Daniel Hilbers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel Hilbers has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- John-Jose Nunez
BC Cancer, Vancouver, BC, Canada
4 shared publications - Alan T. Bates
BC Cancer, Vancouver, BC, Canada
3 shared publications - Navid Nekain
Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
3 shared publications - Ahmad Fayaz-Bakhsh
School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication Alan T Bates
Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada
1 shared publication- Chhavi Nayyar
Faculty of Science, University of British Columbia, Vancouver, BC, Canada
1 shared publication
Latest Publications
- Open Access
Towards clinical implementation of artificial intelligence in cancer care: Concept mapping analysis of provincial workshop findings
Background: Artificial intelligence (AI) has rapidly garnered interest in healthcare, with research showing promise to improve quality, efficiency, and outcomes. Cancer care’s multidisciplinary nature and high coordination demands are well positioned to benefit from AI. While attitudes in the uptake of evidence and toward the implementation of AI in medicine has been explored generally, literature remains scarce with specific regards to AI in cancer care. This study sought to understand how perspectives of both patients and professionals are essential for guiding responsible, effective implementation of evidence-based (EB) AI in cancer care. Methods: We conducted a workshop at the 2024 British Columbia (BC) Cancer Summit (Vancouver, Canada). Discussions addressed three guiding questions: concerns, benefits, and priorities for AI in cancer care. Responses from 48 workshop participants (patients and families, AI/computer science/cancer researchers, clinicians and allied health professionals, information technology professionals, healthcare administrators) underwent structured conceptualization by concept mapping, leveraging multidimensional scaling and hierarchical cluster and subcluster analysis to produce visual and quantitative maps of stakeholder priorities. Results: A total of 265 statements on perceived benefits, concerns, and priorities related to the implementation of AI in cancer care were generated from the workshop and underwent concept mapping. Two clusters were identified; Cluster 1 focused on “Challenges and Safeguards for AI Implementation,” and Cluster 2 focused on “Clinical Benefits and Efficiency Gains.” Subcluster analysis distinguished 8 thematic subclusters (4 per cluster). Both mean importance ( P < .001) and feasibility ( P < .001) ratings were significantly higher for Cluster 2. No differences were found between ratings by clinical and nonclinical professionals. Further go-zone analysis classified statements according to their relative superiority/inferiority in importance and feasibility compared to the overall average. Conclusions: Stakeholder ratings were higher for statements describing clinical benefits and efficiency gains than for those describing challenges and safeguards for AI implementation in cancer care. Concept mapping analysis distinguished between workflow-aligned AI applications, perceived as ready for implementation, and system-level governance requirements requiring longer-term investment. Present findings provide a structured, stakeholder-informed framework for prioritizing and sequencing AI implementation efforts in cancer care, constituting a practical blueprint to catalyze meaningful progress.
Open AccessTowards clinical implementation of artificial intelligence in cancer care: Concept mapping analysis of provincial workshop findings
Background: Artificial intelligence (AI) has rapidly garnered interest in healthcare, with research showing promise to improve quality, efficiency, and outcomes. Cancer care’s multidisciplinary nature and high coordination demands are well positioned to benefit from AI. While attitudes in the uptake of evidence and toward the implementation of AI in medicine has been explored generally, literature remains scarce with specific regards to AI in cancer care. This study sought to understand how perspectives of both patients and professionals are essential for guiding responsible, effective implementation of evidence-based (EB) AI in cancer care. Methods: We conducted a workshop at the 2024 British Columbia (BC) Cancer Summit (Vancouver, Canada). Discussions addressed three guiding questions: concerns, benefits, and priorities for AI in cancer care. Responses from 48 workshop participants (patients and families, AI/computer science/cancer researchers, clinicians and allied health professionals, information technology professionals, healthcare administrators) underwent structured conceptualization by concept mapping, leveraging multidimensional scaling and hierarchical cluster and subcluster analysis to produce visual and quantitative maps of stakeholder priorities. Results: A total of 265 statements on perceived benefits, concerns, and priorities related to the implementation of AI in cancer care were generated from the workshop and underwent concept mapping. Two clusters were identified; Cluster 1 focused on “Challenges and Safeguards for AI Implementation,” and Cluster 2 focused on “Clinical Benefits and Efficiency Gains.” Subcluster analysis distinguished 8 thematic subclusters (4 per cluster). Both mean importance ( P < .001) and feasibility ( P < .001) ratings were significantly higher for Cluster 2. No differences were found between ratings by clinical and nonclinical professionals. Further go-zone analysis classified statements according to their relative superiority/inferiority in importance and feasibility compared to the overall average. Conclusions: Stakeholder ratings were higher for statements describing clinical benefits and efficiency gains than for those describing challenges and safeguards for AI implementation in cancer care. Concept mapping analysis distinguished between workflow-aligned AI applications, perceived as ready for implementation, and system-level governance requirements requiring longer-term investment. Present findings provide a structured, stakeholder-informed framework for prioritizing and sequencing AI implementation efforts in cancer care, constituting a practical blueprint to catalyze meaningful progress.
- Open Access
- 22 August 2025
- Published by JMIR Publications Inc. in JMIR Cancer
- Vol. 11 (1) , e74010
Patient Attitudes Toward Artificial Intelligence in Cancer Care: Scoping Review
Background: Artificial intelligence is reshaping cancer care, but little is known about how people with cancer perceive its integration into their care. Understanding these perspectives is essential to ensuring artificial intelligence adoption aligns with patient needs and preferences while supporting a patient-centered approach. Objective: The aim of this study is to synthesize existing literature on patient attitudes toward artificial intelligence in cancer care and identify knowledge gaps that can inform future research and clinical implementation. Methods: A scoping review was conducted following the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) guidelines. MEDLINE, Embase, PsycINFO, and CINAHL were searched for peer-reviewed primary research studies published until February 1, 2025. The Population-Concept-Context framework guided study selection, focusing on adult patients with cancer and their attitudes toward artificial intelligence. Studies with quantitative or qualitative data were included. Two independent reviewers screened studies, with a third resolving disagreements. Data were synthesized into tabular and narrative summaries. Results: Our search yielded 1240 citations, of which 19 studies met the inclusion criteria, representing 2114 patients with cancer across 15 countries. Most studies used quantitative methods (9/19, 47%) such as questionnaires or surveys. The most studied cancers were melanoma (375/2114, 17.7%), prostate (n=323, 15.3%), breast (n=263, 12.4%), and colorectal cancer (n=251, 11.9%). Although patients with cancer generally supported artificial intelligence when used as a physician-guided tool (9/19, 47%), concerns about depersonalization, treatment bias, and data security highlighted challenges in implementation. Trust in artificial intelligence (10/19, 53%) was shaped by physician endorsement and patient familiarity, with greater trust when artificial intelligence was physician-guided. Geographic differences were observed, with greater artificial intelligence acceptance in Asia, while skepticism was more prevalent in North America and Europe. Additionally, patients with metastatic cancer (99/2114, 5%) were underrepresented, limiting insights into artificial intelligence perceptions in this population. Conclusions: This scoping review provides the first synthesis of patient attitudes toward artificial intelligence across all cancer types and highlights concerns unique to patients with cancer. Clinicians can use these findings to enhance patient acceptance of artificial intelligence by positioning it as a physician-guided tool and ensuring its integration aligns with patient values and expectations.
- 22 August 2025
- Published by JMIR Publications Inc. in JMIR Cancer
- Vol. 11 (1) , e74010
Open AccessPatient Attitudes Toward Artificial Intelligence in Cancer Care: Scoping Review
Background: Artificial intelligence is reshaping cancer care, but little is known about how people with cancer perceive its integration into their care. Understanding these perspectives is essential to ensuring artificial intelligence adoption aligns with patient needs and preferences while supporting a patient-centered approach. Objective: The aim of this study is to synthesize existing literature on patient attitudes toward artificial intelligence in cancer care and identify knowledge gaps that can inform future research and clinical implementation. Methods: A scoping review was conducted following the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) guidelines. MEDLINE, Embase, PsycINFO, and CINAHL were searched for peer-reviewed primary research studies published until February 1, 2025. The Population-Concept-Context framework guided study selection, focusing on adult patients with cancer and their attitudes toward artificial intelligence. Studies with quantitative or qualitative data were included. Two independent reviewers screened studies, with a third resolving disagreements. Data were synthesized into tabular and narrative summaries. Results: Our search yielded 1240 citations, of which 19 studies met the inclusion criteria, representing 2114 patients with cancer across 15 countries. Most studies used quantitative methods (9/19, 47%) such as questionnaires or surveys. The most studied cancers were melanoma (375/2114, 17.7%), prostate (n=323, 15.3%), breast (n=263, 12.4%), and colorectal cancer (n=251, 11.9%). Although patients with cancer generally supported artificial intelligence when used as a physician-guided tool (9/19, 47%), concerns about depersonalization, treatment bias, and data security highlighted challenges in implementation. Trust in artificial intelligence (10/19, 53%) was shaped by physician endorsement and patient familiarity, with greater trust when artificial intelligence was physician-guided. Geographic differences were observed, with greater artificial intelligence acceptance in Asia, while skepticism was more prevalent in North America and Europe. Additionally, patients with metastatic cancer (99/2114, 5%) were underrepresented, limiting insights into artificial intelligence perceptions in this population. Conclusions: This scoping review provides the first synthesis of patient attitudes toward artificial intelligence across all cancer types and highlights concerns unique to patients with cancer. Clinicians can use these findings to enhance patient acceptance of artificial intelligence by positioning it as a physician-guided tool and ensuring its integration aligns with patient values and expectations.
- Open Access
Patient Attitudes Toward Artificial Intelligence in Cancer Care: A Scoping Review
PURPOSE: To synthesize existing literature on patient attitudes toward AI in cancer care and identify knowledge gaps that can inform future research and clinical implementation. DESIGN: A scoping review was conducted following PRISMA-ScR guidelines. MEDLINE, EMBASE, PsycINFO, and CINAHL were searched for peer-reviewed primary research studies published until February 1, 2025. The Population-Concept-Context framework guided study selection, focusing on adult patients with cancer and their attitudes toward AI. Studies with quantitative or qualitative data were included. Two independent reviewers screened studies, with a third resolving disagreements. Data were synthesized into tabular and narrative summaries. RESULTS: Our search yielded 1,240 citations, of which 19 studies met the inclusion criteria, representing 2,114 patients with cancer across 15 countries. Most studies used quantitative methods (n=9) such as questionnaires or surveys. The most studied cancers were prostate, melanoma, breast, and colorectal cancer. While patients with cancer generally supported AI when used as a physician-guided tool, concerns about depersonalization, treatment bias, and data security highlighted challenges in implementation. Trust in AI was shaped by physician endorsement and patient familiarity, with greater trust when AI was physician-guided. Geographic differences were observed, with greater AI acceptance in Asia, while skepticism was more prevalent in North America and Europe. Additionally, patients with metastatic cancer were underrepresented, limiting insights into AI perceptions in this population. CONCLUSION: This scoping review provides the first synthesis of patient attitudes toward AI across all cancer types and highlights concerns unique to patients with cancer. Clinicians can use these findings to enhance patient acceptance of AI by positioning it as a physician-guided tool and ensuring its integration aligns with patient values and expectations.
Open AccessPatient Attitudes Toward Artificial Intelligence in Cancer Care: A Scoping Review
PURPOSE: To synthesize existing literature on patient attitudes toward AI in cancer care and identify knowledge gaps that can inform future research and clinical implementation. DESIGN: A scoping review was conducted following PRISMA-ScR guidelines. MEDLINE, EMBASE, PsycINFO, and CINAHL were searched for peer-reviewed primary research studies published until February 1, 2025. The Population-Concept-Context framework guided study selection, focusing on adult patients with cancer and their attitudes toward AI. Studies with quantitative or qualitative data were included. Two independent reviewers screened studies, with a third resolving disagreements. Data were synthesized into tabular and narrative summaries. RESULTS: Our search yielded 1,240 citations, of which 19 studies met the inclusion criteria, representing 2,114 patients with cancer across 15 countries. Most studies used quantitative methods (n=9) such as questionnaires or surveys. The most studied cancers were prostate, melanoma, breast, and colorectal cancer. While patients with cancer generally supported AI when used as a physician-guided tool, concerns about depersonalization, treatment bias, and data security highlighted challenges in implementation. Trust in AI was shaped by physician endorsement and patient familiarity, with greater trust when AI was physician-guided. Geographic differences were observed, with greater AI acceptance in Asia, while skepticism was more prevalent in North America and Europe. Additionally, patients with metastatic cancer were underrepresented, limiting insights into AI perceptions in this population. CONCLUSION: This scoping review provides the first synthesis of patient attitudes toward AI across all cancer types and highlights concerns unique to patients with cancer. Clinicians can use these findings to enhance patient acceptance of AI by positioning it as a physician-guided tool and ensuring its integration aligns with patient values and expectations.
- Open Access
- 14 January 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (1) , e0317276
Patients’ attitudes toward artificial intelligence (AI) in cancer care: A scoping review protocol
Background: Artificial intelligence broadly refers to computer systems that simulate intelligent behaviour with minimal human intervention. Emphasizing patient-centered care, research has explored patients’ perspectives on artificial intelligence in medical care, indicating general acceptance of the technology but also concerns about supervision. However, these views have not been systematically examined from the perspective of patients with cancer, whose opinions may differ given the distinct psychosocial toll of the disease. Objectives: This protocol describes a scoping review aimed at summarizing the existing literature on the attitudes of patients with cancer toward the use of artificial intelligence in their medical care. The primary goal is to identify knowledge gaps and highlight opportunities for future research. Methods: This scoping review protocol will adhere to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PRISMA-ScR). The electronic databases MEDLINE (OVID), EMBASE, PsycINFO, and CINAHL will be searched for peer-reviewed primary research articles published in academic journals. We will have two independent reviewers screen the articles retrieved from the literature search and select relevant studies based on our inclusion criteria, with a third reviewer resolving any disagreements. We will then compile the data from the included articles into a narrative summary and discuss the implications for clinical practice and future research. Discussion: To our knowledge, this will be the first scoping review to map the existing literature on the attitudes of patients with cancer regarding artificial intelligence in their medical care.
- 14 January 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (1) , e0317276
Open AccessPatients’ attitudes toward artificial intelligence (AI) in cancer care: A scoping review protocol
Background: Artificial intelligence broadly refers to computer systems that simulate intelligent behaviour with minimal human intervention. Emphasizing patient-centered care, research has explored patients’ perspectives on artificial intelligence in medical care, indicating general acceptance of the technology but also concerns about supervision. However, these views have not been systematically examined from the perspective of patients with cancer, whose opinions may differ given the distinct psychosocial toll of the disease. Objectives: This protocol describes a scoping review aimed at summarizing the existing literature on the attitudes of patients with cancer toward the use of artificial intelligence in their medical care. The primary goal is to identify knowledge gaps and highlight opportunities for future research. Methods: This scoping review protocol will adhere to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PRISMA-ScR). The electronic databases MEDLINE (OVID), EMBASE, PsycINFO, and CINAHL will be searched for peer-reviewed primary research articles published in academic journals. We will have two independent reviewers screen the articles retrieved from the literature search and select relevant studies based on our inclusion criteria, with a third reviewer resolving any disagreements. We will then compile the data from the included articles into a narrative summary and discuss the implications for clinical practice and future research. Discussion: To our knowledge, this will be the first scoping review to map the existing literature on the attitudes of patients with cancer regarding artificial intelligence in their medical care.